ANTAEA GCP training recognized by TransCelerate BioPharma Inc.
ANTAEA training GCP for Every Day Use has been added to the list of training Self Attested, as meeting the minimum criteria identified by TransCelerate BioPharma Inc.
ANTAEA GCP Training
GCP for Every Day Use provides a comprehensive overview of ICH-GCP combined with useful tips and hints to physicians – Investigators and their teams involved in clinical trials.
It is one of series of modular courses developed by ANTAEA Medical Services Ltd. The objective is to provide health care professionals with a sound working knowledge of ICH-GCP Guidelines in order to apply them effectively and efficiently in their research work as well as medical practice. The course GCP for Every Day Use lasts 2 days counting for 18 CPD hours; it is certified by Continuing Professional Development Service in the United Kingdom.
This ICH E6 GCP Investigator Site Training meets the Minimum Criteria for ICH GCP Investigator Site Personnel Training identified by TransCelerate BioPharma as necessary to enable mutual recognition of GCP training among clinical trial sponsors. This means that Investigators and their teams who pass the GCP for Every Day Use course reduce the likelihood of being requested to take additional GCP trainings by individual study sponsors participating in the program, support sponsor companies mutually recognizing GCP training, and may focus on patient recruitment and treatment as well as other study tasks.
Commenting on the announcement, Mr. John Roussos, BSc, MSc MedPhys, the Chief Executive Officer of the ANTAEA Group, said: “ANTAEA strongly believes in the value of training as one of the means of continuing professional development and growth. Due to ongoing rapid advances in health care, constant flow of new information and limited physicians’ time, the need for a smart design of training courses is essential. Our goal is to deliver courses grounded in knowledge and experience, visually attractive, interactive and practical so that all course attendees may readily apply what they have learned. We appreciate that TransCelerate BioPharma has added our course to the list online as self attested by third-party GCP training vendors for meeting the minimum criteria for GCP training.”
TransCelerate BioPharma Inc. is a non-profit organisation dedicated to accelerating and simplifying the research and development of innovative new therapies. The organisation’s mission is to collaborate across the global biopharmaceutical R&D community to identify, prioritise, design and facilitate implementation of solutions designed to drive the efficient, effective and high quality delivery of new medicines. The founding member companies are AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Pfizer, the Roche Group, and Sanofi. Additional members that have joined since the inception of TransCelerate include Actavis, Allergan, Inc., Astellas Pharma Inc., Biogen, Cubist Pharmaceuticals, EMD Serono, Inc. (a subsidiary of Merck KGaA, Darmstadt, Germany), Medgenics, Inc., Merck & Co., Inc., Novo Nordisk A/S, Shionogi & Co., Ltd. and UCB.
About ANTAEA Group
ANTAEA Group is a CRO with 17-year experience in clinical research field. We provide services to the pharmaceutical, biotechnology and medical device industries as well as Academic institutions and hospitals. ANTAEA Group specialises in clinical trials, registration and regulatory affairs, EDC, trainings and medical writing.
ANTAEA Group is a Regional CRO providing Regulatory Authorities’ recognised quality services in South-East Europe, Middle East and Africa with coverage in Cyprus, Egypt, Ghana, Greece, the Gulf states, Jordan, Lebanon, Morocco, Saudi Arabia, Sudan and Tunisia.
